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Abstract   
Nonsense-mediated mRNA decay (NMD) is
a surveillance system to prevent the synthesis
of non-functional proteins. In β-thalassemia,
NMD may have a role in clinical outcome. An
example of premature translation stop codons
appearing for the first time is the β-globin
cd39 mutation; when homozygous, this results
in a severe phenotype. The aim of this study
was to determine whether the homozygous
nonsense cd39 may have a milder phenotype in
comparison with IVS1,nt110/cd39 genotype.
Genotypes have been identified from a cohort
of 568 patients affected by β-thalassemia.
These genotypes were compared with those
found in 577 affected fetuses detected among
2292 prenatal diagnoses. The nine most com-
mon genotypes, each with an incidence rate of
1.5% or over, and together accounting for 80%
of genotype frequencies, underwent statistical
analysis. Genotype prevalence was calculated
within the overall group. Results are expressed
as proportions with 95% confidence intervals;
P≤0.05 was considered statistically significant.
A binomial distribution was assumed for each
group; z-tests were used to compare genotype
frequencies observed in the patient group with
frequencies in the affected fetus group. In the
absence of selecting factors, prevalence of
these two genotypes was compared between a
cohort of 568 β-thalassemia patients (PTS)
and 577 affected fetuses (FOET) detected dur-
ing the same period. IVS1,nt110/cd39 was sig-
nificantly more prevalent in FOET than PTS
(P<0.0001), while there was no significant dif-
ference in prevalence of  cd39/cd39 in FOET
compared with PTS (P=0.524). These results
suggest a cd39 genotype NMD mechanism may
be associated with improved clinical outcomes
in thalassemia major.
Introduction 
Messenger RNA (mRNA) stability is a criti-
cal determinant that affects gene expression.
Studies in yeast and other model eukaryotic
organisms have revealed many pathways to
modulate mRNA stability in response to devel-
opmental, physiological and/or environmental
stimuli.1
Nonsense-mediated mRNA decay (NMD) is
a post-transcriptional process in eukaryotic
cells by which transcripts from premature
translation stop codons (PTCs)2 are recognized
by NMD factors and rapidly degraded.3
The exact molecular mechanism for NMD in
higher eukaryotes is still being investigated.
Degradation occurs when the nonsense codon
is at least 50-55 nucleotides upstream of the
exon-exon junction.4,5
Nonsense and frameshift mutations are
present in approximately one-third of point
mutations that cause human genetic disor-
ders.6 Phenotypes of genetic diseases are,
therefore, likely to be frequently affected by
NMD. NMD can affect clinical outcome in at
least three important ways: i) altering the pat-
tern of inheritance; ii) causing distinct traits
to manifest from mutations in the same gene;
and iii) modifying specific clinical pheno-
types.3
β-thalassemia is a genetic disease in which
PTCs may have a role in specific homozygous
genotype for the nonsense cd39 mutation,
described as a severe phenotype.
Furthermore, β-thalassemia is the first
genetic disorder in which it was shown how
NMD is involved in the clinical outcome of
genetic disorders: NMD-activating nonsense
mutations result in a recessive mode of inher-
itance with asymptomatic heterozygous carri-
ers, whereas nonsense mutations bypassing
the NMD mechanism are characterized by a
dominant mode of inheritance resulting in a
rare form of symptomatic heterozygous β-tha-
lassemia.7,8
However, whether the β-thalassemia NMD
mechanism in homozygous nonsense cd39
may be involved in improving clinical out-
comes is not yet known. 
Therefore, the aim of this study was to
determine whether the homozygous nonsense
cd39 mutation, because of a PTC mechanism,
may have a milder phenotype in comparison
with that of a heterozygous cd39/IVS1,nt110.
Furthermore, the translation of aberrant
IVS1,nt110 β-globin mRNA to detect the pres-
ence of NMD was analyzed.
Materials and Methods
In the absence of selecting factors, preva-
lence of homozygous nonsense cd39 and com-
pound IVS1,nt110/cd39 genotypes, was com-
pared between a cohort of 568 affected β-tha-
lassemia patients (PTS) and 577 affected
fetuses (FOET) detected during the same peri-
od among 2292 prenatal diagnoses.
In the absence of selection bias, the preva-
lence of β-thalassemia molecular defects in
affected fetuses should be similar to that found
in β-thalassemia patients.
Possible biases influencing these findings
could include: i) the effects of improvements
in transfusion and chelation therapy in the dif-
ferent genotypes; and ii) prenatal diagnosis
sought by some at-risk couples with differenti-
ated genotypes. It is evident that neither bias
currently exists, reflecting that both manage-
ment of thalassemia major and prenatal diag-
nosis programs are carried out independently
of thalassemia genotypes. 
Therefore, any significant difference in the
prevalence of these genotypes between fetuses
and adults would be caused by the effect of
genotype on phenotype.
Thalassemia Reports 2012; volume 2:e2
Correspondence: Aurelio Maggio, U.O.C.
Ematologia per le Malattie Rare del Sangue e
degli Organi Ematopoietici, Ospedali Riuniti Villa
Sofia-Cervello, via Trabucco 180, 90146 Palermo,
Italy. 
Tel. +39.91.688.5251 - Fax: +39.91.688.0228. 
E-mail: aurelio.maggio@ospedaliriuniti.it
Key words: nonsense-mediated mRNA decay,
beta-thalassemia, clinical outcame, beta-globin
gene mutations. 
Acknowledgments: the authors would like to
thank the Foundation Franco and Piera Cutino
for its support.
Contributions: AM, MCR, research coordination
and manuscript writing; AV, MA, statistical analy-
sis; AP, EF, AG, GF, MCR, FC, laboratory investiga-
tion; DR, PR, GC, patients recruitment; AM, paper
principal investigator and responsible.
Conflict of interests: the authors declare no
potential conflict of interests.
Received for publication: 24 May 2012.
Revision received: 23 August 2012.
Accepted for publication: 28 September 2012.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0).
©Copyright M.C. Renda et al., 2012
Licensee PAGEPress, Italy
Thalassemia Reports 2012; 2:e2
doi:10.4081/thal.2012.e2
No
n-c
om
er
l u
se
 on
ly
[page 4] [Thalassemia Reports 2012; 2:e2]
Genotype analysis
Since 1993, genotypes have been identified
at the Hematology Unit for Rare Blood and
Hematopoietic Organ Diseases, at the Riuniti
Villa Sofia-Cervello Hospital, Palermo, Italy,
from a cohort of 568 patients affected by β-
thalassemia syndromes. These genotypes
were compared with those found in 577
affected fetuses detected during the same
period among 2292 prenatal diagnoses per-
formed by chorionic villi sampling and DNA
molecular analysis. The diagnosis of tha-
lassemia was based on accepted clinical and
molecular criteria.9,10Statistical analysis 
Ninety-four different genotypes were found
among the two groups. The nine most com-
mon genotypes, each with an incidence rate
of 1.5% or over, and together accounting for
80% of detected genotype frequency, under-
went statistical analysis (Table 1). Affected
fetuses with one of these genotypes were
labeled FOET (297 fetuses), and affected β-
thalassemia patients were labeled PTS (313
patients) (Figure 1). Genotype prevalence
was calculated within the overall group (Table
1). If genotype impairs phenotype, in the
absence of selecting factors, its prevalence
should be higher in FOET than in PTS.
Instead, if genotype improves phenotype, its
prevalence should be higher in PTS than in
FOET.  
The analysis is mainly based on a compari-
son between genotype cd39/IVS1,nt110 and
genotype cd39/cd39. Both genotypes identify a
cohort of patients with thalassemia major
who, over the last few years, received the
same chelation treatment and transfusions.
No patients included in this analysis showed
a transition from thalassemia major pheno-
type to thalassemia intermedia phenotype.
The patients included in this cohort were
negative for the deletions of alpha globin
gene -3.7, -4.2 and -MED, and for the HPFH
mutations of G-gamma globin gene promot-
ers. The G-gamma -158 mutation was not
present in the cohort of patients with tha-
lassemia major, since this variant is in link-
age with the mutation IVS1,nt6, whose pres-
ence resulted in a statistically significant dif-
ference between the two groups, FOET versus
PTS (Table 1). 
Results are expressed as proportions with
95% confidence intervals (CI); P≤0.05 was
considered statistically significant. A binomi-
al distribution was assumed for each group; z-
tests were used to compare genotype frequen-
cies observed in the patient group with fre-
quencies in the affected fetus group.11
Statistical tests were performed using STATA
9.2 software (StataCorp, College Station, TX,
USA)
cDNA analysis
Total RNA was extracted from IVS1,nt110
homozygous β-thalassemia patients with
Trizol reagent (Gibco-BRL, Gaithersburg, MD,
USA). Reverse transcription was performed
with 1 mg mRNA, an oligo-dT primer, and 200U
M-MLV. PCR of β-globin cDNA was performed
using the following human beta-globin specif-
ic primers: forward-CTCCTGAGGAGAAGTCT-
GCCG and reverse-GCTCACTCAGTGTG-
GCAAAG. PCR products were investigated by
direct genomic sequencing (CEQ8800-
Beckman). 
Results 
Table 1 shows genotype frequency in the
PTS and FOET groups. There was no signifi-
cant difference in genotype prevalence of
homozygous nonsense cd39 genotype between
FOET versus PTS (z=-0.637, P=0.524) (Table
1). Only IVS1,nt110/cd39 was significantly
more prevalent in FOET than PTS (z=-4.344,
P<0.0001). Instead, the prevalence of
IVS1nt6/IVS1nt6 genotype was significantly
higher in PTS than in FOET (18% vs 2%;
z=7.17, P<0.00001).
Figure 2 shows the sequencing of β-globin
cDNA-PCR products from an IVS1,nt110
homozygous patient; interruption of the frame
Article
Table 1. Comparison between prevalence of patient genotypes and genotypes of β-tha-
lassemia affected fetuses (1993-2006). 
Genotype nPTS (%) nFOET (%) z IC P
IVS1nt110-cod39 40(11.5) 78 (24) -4.344 (-0.18;-0.07) 0.00001
IVS1nt110-IVS1nt1 14(4) 22(6.8) -1.606 (-0.06;0.006) 0.108
cod39-IVS2nt745 14(4) 15(4.6) -0.409 (-0.03;0.02) 0.682
IVS1nt110-IVS1nt110 37(10.5) 42(13) -0.975 (-0.07;0.02) 0.330
cod39-IVS1nt1 10(2.9) 16(4.9) -1.397 (-0.05;0.008) 0.162
cod39-cod39 45(12.9) 47(14.5) -0.637 (-0.06;0.03) 0.524
cod39-IVS1nt6 55(15.5) 47(14.5) 0.422 (-0.04;0.06) 0.673
IVS1nt110-IVS1nt6 35(10 ) 23(7.1) 1.340 (-0.01;0.07) 0.180
IVS1nt6-IVS1nt6 63(18) 7(2) 7.170 (0.11;0.2) <0.0001
nPTS, number β-thalassemia patients; nFOET, number affected fetuses; z, z-test score; IC, immediate constituent analysis. 
Figure 1. Profile of study to evaluate β-thalassemia genotypes found in the two groups
considered.
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sequence indicates that both normal mRNA
and  abnormal mRNA containing a sequence
19 nucleotides longer are present.
Conclusions 
Molecular defects of the β-globin gene have
been well characterized and, to date, more
than 200 β-thal mutations have been
described.12 It is well known that some β-tha-
lassemia genotypes, such as nonsense cd39
homozygous, are especially severe, due to the
complete lack of β-globin chain synthesis and
the resulting imbalance of alpha-globin.
Therefore, its prevalence in FOET would have
been higher than in PTS (Table 1).
However, our findings suggest that the clin-
ical outcomes of patients with cd39 homozy-
gous are no different from those in other
severe genotypes with lower but present β-glo-
bin chain synthesis (Table 1), probably
because of the NMD mechanism.3 NMD repre-
sents one of the major quality-control path-
ways of the cell. In most described cases, NMD
is splicing-dependent, always translation-
dependent, and relies on the interaction of the
translation apparatus with the exon junction
complexes or on the distance between the
PTC.2 The more severe phenotype in the
IVS1,nt110/cd39 genotype (z=-4.344,
P<0.0001) (Table 1) could be explained by the
lack of NMD mechanism in the chromosome
with the IVS1,nt110. This mutation produces
abnormal β-globin transcripts, containing a
sequence 19 nucleotides longer, inserting a
new PTC (UAG) at nt16.
The molecular cDNA analysis of a small
group of these patients confirms the lack of
NMD mechanism in the chromosome with the
IVS1,nt110 (Figure 1).
Our data show that, in β-globin IVS1,nt110
G>A mutation, NMD is probably disabled.         
The expression of a human β-globin gene
with the IVS1,nt110G>A mutation causes the
presence of a faulty and frame-shifted mRNA,
expected to encode anomalous and C-terminal-
ly truncated β-globin chains that are detrimen-
tal to cells, although the new insert PTC is
more than 55 nt upstream of the next intron-
exon junction (Figure 1).12-15 The majority of
abnormal β-globin transcripts in homozygous
IVS1,nt110 could be due to their different clin-
ical outcome in comparison with
IVS1nt110/cd39 genotype (Table 1). Actually, in
homozygous IVS1,nt110, the majority of abnor-
mal β-globin transcripts could easily be metab-
olized or assembled into more functional pro-
tein complexes. The milder phenotype of
IVS1,nt6, has been identified previously and
was confirmed by these findings.16
The limitation of the study may be the pres-
ence of other genetic modifier factors influ-
encing survival curves.17
In conclusion, the role of NMD as a modifier
of the phenotypic consequences of PTC,
already shown in other genetic diseases,3 is
becoming more apparent in β-thalassemia
syndromes, and the position of a nonsense
mutation alone is not sufficient to predict the
fate of the affected mRNA and its effect on pro-
tein expression.
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